Current Price and Market Context
As of 13 Aug 2026, Sudarshan Pharma closed at ₹34.51, marking a 1.77% increase from the previous close of ₹33.91. The stock traded within a range of ₹34.02 to ₹35.60 during the day, remaining well below its 52-week high of ₹42.79 but comfortably above the 52-week low of ₹18.50. This price movement reflects a recovery phase after a period of consolidation, supported by a mild bullish technical trend.
Technical Trend Evolution
The stock’s technical trend has evolved from a sideways pattern to a mildly bullish one, signalling a potential shift in investor sentiment. This change is corroborated by the daily moving averages, which are currently mildly bullish, indicating that short-term momentum is gaining traction. The KST (Know Sure Thing) indicator on a weekly basis also supports this mild bullishness, although monthly KST data remains inconclusive.
MACD and RSI Analysis
The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. Both weekly and monthly MACD readings remain mildly bearish, suggesting that while short-term momentum is improving, the broader trend still faces some downward pressure. This divergence between daily moving averages and MACD highlights a transitional phase where momentum is building but not yet fully confirmed.
The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, hovering in neutral territory. This lack of overbought or oversold conditions implies that the stock has room to move in either direction, making it essential for investors to monitor upcoming price action closely.
Bollinger Bands and Price Volatility
Bollinger Bands provide further insight into the stock’s volatility and momentum. On a weekly basis, the bands are bullish, indicating that price is trending towards the upper band, a sign of strengthening momentum. Monthly Bollinger Bands are mildly bullish, reinforcing the notion of a gradual upward shift. This suggests that volatility is increasing in favour of buyers, which could support further price appreciation if sustained.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Dow Theory and On-Balance Volume (OBV)
According to Dow Theory, the weekly trend remains mildly bearish, reflecting some caution among traders in the short term. However, the monthly Dow Theory trend is mildly bullish, suggesting that the longer-term outlook is more positive. This divergence underscores the transitional nature of the stock’s momentum.
On-Balance Volume (OBV) data is not available for this stock, which limits the ability to assess volume-driven momentum conclusively. Investors should therefore rely more heavily on price and moving average signals in the near term.
Comparative Returns and Market Performance
When compared to the broader Sensex index, Sudarshan Pharma has outperformed significantly over multiple time horizons. The stock delivered a 6.22% return over the past week against a Sensex decline of 0.78%. Year-to-date, the stock has surged 25.26%, while the Sensex has fallen 8.51%. Over one year, Sudarshan Pharma gained 13.59% compared to the Sensex’s 2.83% decline. The most striking performance is over three years, where the stock returned an impressive 372.74%, dwarfing the Sensex’s 19.36% gain.
These returns highlight the stock’s strong relative momentum despite its micro-cap status and the volatility inherent in the Specialty Chemicals sector.
Mojo Score and Rating Update
MarketsMOJO assigns Sudarshan Pharma a Mojo Score of 58.0, reflecting a Hold rating. This is a downgrade from the previous Buy rating as of 30 Jul 2026. The downgrade reflects the mixed technical signals and the cautious stance warranted by the mildly bearish MACD and Dow Theory weekly trends. The micro-cap classification also suggests higher risk and volatility, which investors should factor into their decision-making.
Sudarshan Pharma Industries Ltd or something better? Our SwitchER feature analyzes this micro-cap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway and Outlook
Sudarshan Pharma’s technical indicators present a complex but cautiously optimistic picture. The shift from sideways to mildly bullish trend, supported by daily moving averages and weekly Bollinger Bands, suggests that the stock is building momentum. However, the mildly bearish MACD and weekly Dow Theory signals counsel prudence, indicating that the stock has not yet fully confirmed a sustained uptrend.
Investors should monitor the RSI for any emerging overbought or oversold conditions and watch for confirmation from monthly indicators to validate the longer-term trend. Given the stock’s strong relative returns versus the Sensex and its micro-cap status, it remains a candidate for selective accumulation by risk-tolerant investors seeking exposure to the Specialty Chemicals sector.
In summary, Sudarshan Pharma Industries Ltd is at a technical inflection point. While the momentum is building, the mixed signals warrant a Hold rating until clearer confirmation of trend direction emerges.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
